Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 2/6 |
Past Performance | 5/6 |
Financial Health | 5/6 |
Dividends | 4/6 |
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | Ft26.80 |
52 Week High | Ft28.32 |
52 Week Low | Ft21.90 |
Beta | 0.37 |
11 Month Change | -2.40% |
3 Month Change | 9.84% |
1 Year Change | 16.42% |
33 Year Change | 11.57% |
5 Year Change | 59.14% |
Change since IPO | 312.94% |
Recent News & Updates
Recent updates
Shareholder Returns
RIG2 | DE Pharmaceuticals | DE Market | |
---|---|---|---|
7D | 0.4% | -1.8% | -1.8% |
1Y | 16.4% | -12.8% | 13.6% |
Return vs Industry: RIG2 exceeded the German Pharmaceuticals industry which returned -12.8% over the past year.
Return vs Market: RIG2 exceeded the German Market which returned 13.6% over the past year.
Price Volatility
RIG2 volatility | |
---|---|
RIG2 Average Weekly Movement | 4.3% |
Pharmaceuticals Industry Average Movement | 7.9% |
Market Average Movement | 5.0% |
10% most volatile stocks in DE Market | 11.5% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: RIG2 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: RIG2's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1901 | 11,603 | Gabor Orban | www.gedeonrichter.com/hu-hu |
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. researches, develops, manufactures, markets, and sells pharmaceutical products worldwide. It operates through two segments, Pharmaceuticals, and Wholesale and Retail.
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. Fundamentals Summary
RIG2 fundamental statistics | |
---|---|
Market cap | €4.84b |
Earnings (TTM) | €562.12m |
Revenue (TTM) | €1.99b |
8.6x
P/E Ratio2.4x
P/S RatioIs RIG2 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
RIG2 income statement (TTM) | |
---|---|
Revenue | Ft811.42b |
Cost of Revenue | Ft260.03b |
Gross Profit | Ft551.39b |
Other Expenses | Ft322.26b |
Earnings | Ft229.13b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 12, 2024
Earnings per share (EPS) | 1.26k |
Gross Margin | 67.95% |
Net Profit Margin | 28.24% |
Debt/Equity Ratio | 9.4% |
How did RIG2 perform over the long term?
See historical performance and comparison